C

동아에스티

170900KOSPI의약품 제조업

46.0 / 100

Reference Date: 2026-06-10

Financial Score12.0 / 40
News Sentiment19.0 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Declined 14.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Dong-A ST, established in 2013 through a spin-off from Dong-A Pharmaceutical, focuses on manufacturing and selling specialty pharmaceuticals, medical devices, and pharmaceutical cosmetics. Key products include Grotrixin, Motiriton, and Suganon, with 2024 sales reaching 697.9 billion won, a 5.1% increase from the previous year. Growth was driven by the biopharmaceutical product Grotrixin and increased overseas exports.

Number of Employees

1,685people

Average Salary

78.9M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 11.934.0Point
PBR
0.54Industry Average 0.895.5Point

Lower than industry avg (good)

ROE
-5.45Industry Average 4.010.0Point

Well below industry avg

Debt Ratio
49.87Industry Average 12.430.0Point

4.0x industry avg (risky)

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲10.5% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼110.6% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -2.8% (declining, 3yr)

Detailed News Sentiment

27 totalPositive 22Neutral 4Negative 1Average Sentiment Score 76.1

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 37,250Won52-week high 55,12552-week low 37,250
1-month return1.0Point

1m -14.07% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral지속가능경영보고서등관련사항(자율공시)2026-06-05
  • Neutral기업지배구조보고서공시2026-06-01
  • Neutral분기보고서 (2026.03)2026-05-15